Ardelyx Stock News

Two new breakout stocks for Week 50 with better than 10% short-term upside potential. This past week two out of four stocks gained over 10% led by peak gains in AQB +103.3% and OPRX +12.7% closing wit

I last wrote about Ardelyx as the company was close to submitting its tenapanor NDA and the stock was trading for over $8. Since that time, Ardelyx had gotten its NDA accepted with an April 29, 2021 P

Ardelyx, Inc. filed an NDA for its chief asset tenapanor in the control of serum phosphorus in adults with chronic kidney disease on dialysis on June 30th, 2020.

Ardelyx (ARDX) delivered earnings and revenue surprises of -3.70% and 63.06%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with kidney and cardiovascular diseases,

Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds' and succes

Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with kidney and cardiovascular diseases,

State Street Corp boosted its holdings in shares of Ardelyx Inc (NASDAQ:ARDX) by 30.0% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The

A look at the shareholders of Ardelyx, Inc. (NASDAQ:ARDX) can tell us which group is most powerful. Institutions will...

Ardelyx (ARDX) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Victory Capital Management Inc. lifted its position in shares of Ardelyx Inc (NASDAQ:ARDX) by 25.3% in the first quarter, according to its most recent disclosure with the SEC. The institutional invest

Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on developing first-in-class medicines to improve treatment for people with kidney and cardiovascular diseases, today announced the su

Insider buying more than doubled last week. Notable Insider Buys: Continental Resources, Inc., AXIS Capital Holdings Limited, Groupon, Inc., Ardelyx, Inc., Epiz

Those following along with Ardelyx, Inc. (NASDAQ:ARDX) will no doubt be intrigued by the recent purchase of shares by...

Ardelyx Inc (NASDAQ:ARDX) Director David M. Mott bought 4,673 shares of the stock in a transaction on Monday, June 22nd. The stock was purchased at an average price of $6.75 per share, with a total va